Fu-An Kang

Fu-An Kang

Company: miRecule

Job title: Vice President Research


Harnessing Novel Antibody Oligonucleotide Conjugates as Targeted miRNA Therapy Inhibiting RTK Signaling & Drug Resistance in Head & Neck Cancer 12:30 pm

miR-30-5p is a critical tumor suppressor in a subset of head and neck cancers targeting multiple Receptor Tyrosine Kinase Pathways MC-30 is a novel targeted therapy mimicking the natural miR-30 gene can reduce drug resistance and may extend progression free survival Novel antibody oligonucleotide conjugates are developed as a promising therapy to treat head and…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.